Metformin in Safety and Efficacy in Gouty Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: placebo, Metformin.
- Who it may be relevant to
- Registry conditions: Gout. Basic parameters: 18 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
the Impact of Metformin Use on Clinical Outcomes in Gouty Patients
Overview
The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients
Interventions
- Other placebo
Placebo will have the same look of metformin - Drug Metformin
Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients
Primary outcome measures
- - Clinical assessment of disease activity [Time frame: 3 months]
Eligibility criteria
Inclusion criteria
- Gouty patients clinically diagnosed as gouty arthritis based on the American College of Rheumatology/European League Against Rheumatism criteria of gout.
Exclusion criteria
- Systemic disorders such as cardiovascular, neurological, coronary artery disease.
- Hypertension, hyperlipidemia, diabetes mellitus, active infections.
- Other inflammatory or autoimmune diseases.
- Patients on biologics,
- Cases with hypersensitivity to metformin and those with impaired liver and kidney functions.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Tanta Unuversity — Tanta
Identifiers
NCT: NCT06924658 · 8746